177 related articles for article (PubMed ID: 32500079)
1. Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells.
Mika T; Maghnouj A; Klein-Scory S; Ladigan-Badura S; Baraniskin A; Thomson J; Hasenkamp J; Hahn SA; Wulf G; Schroers R
Front Mol Biosci; 2020; 7():84. PubMed ID: 32500079
[TBL] [Abstract][Full Text] [Related]
2. Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients.
Haderbache R; Warda W; Hervouet E; da Rocha MN; Trad R; Allain V; Nicod C; Thieblemeont C; Boissel N; Varlet P; Agha IY; Bouquet L; Guiot M; Venet F; Sujobert P; Roussel X; Rouzaire PO; Caillot D; Casasnovas O; Bories JC; Bachy E; Caillat-Zucman S; Deschamps M; Ferrand C
J Transl Med; 2021 Jun; 19(1):265. PubMed ID: 34154602
[TBL] [Abstract][Full Text] [Related]
3. Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel.
Fehse B; Badbaran A; Berger C; Sonntag T; Riecken K; Geffken M; Kröger N; Ayuk FA
Mol Ther Methods Clin Dev; 2020 Mar; 16():172-178. PubMed ID: 32055645
[TBL] [Abstract][Full Text] [Related]
4. Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR.
Badbaran A; Berger C; Riecken K; Kruchen A; Geffken M; Müller I; Kröger N; Ayuk FA; Fehse B
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32698364
[TBL] [Abstract][Full Text] [Related]
5. Quantification of cell-free DNAfor the analysis of CD19-CAR-T cells during lymphoma treatment.
Mika T; Thomson J; Nilius-Eliliwi V; Vangala D; Baraniskin A; Wulf G; Klein-Scory S; Schroers R
Mol Ther Methods Clin Dev; 2021 Dec; 23():539-550. PubMed ID: 34853800
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Schubert ML; Dietrich S; Stilgenbauer S; Schmitt A; Pavel P; Kunz A; Bondong A; Wegner M; Stadtherr P; Jung S; Ho AD; Müller-Tidow C; Schmitt M; Dreger P
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1575-1580. PubMed ID: 32422254
[TBL] [Abstract][Full Text] [Related]
7. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
8. A Real-Time Quantitative PCR Targeting the Viral Vector for the Monitoring of Patients Treated with Axicabtagene Ciloleucel.
Baras A; Bocket L; Beauvais D; Hallaert C; Varlet P; Yakoub-Agha I; Hober D; Alidjinou EK
J Mol Diagn; 2021 Apr; 23(4):447-454. PubMed ID: 33385585
[TBL] [Abstract][Full Text] [Related]
9. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E
Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738
[TBL] [Abstract][Full Text] [Related]
10. Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma.
Jain MD; Bachmeier CA; Phuoc VH; Chavez JC
Ther Clin Risk Manag; 2018; 14():1007-1017. PubMed ID: 29910620
[TBL] [Abstract][Full Text] [Related]
11. Monitoring anti-CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction.
Cheng J; Mao X; Chen C; Long X; Chen L; Zhou J; Zhu L
Cytometry A; 2023 Jan; 103(1):16-26. PubMed ID: 35875964
[TBL] [Abstract][Full Text] [Related]
12. Unlocking Predictive Power: Quantitative Assessment of CAR-T Expansion with Digital Droplet Polymerase Chain Reaction (ddPCR).
Galli E; Viscovo M; Fosso F; Pansini I; Di Cesare G; Iacovelli C; Maiolo E; Sorà F; Hohaus S; Sica S; Bellesi S; Chiusolo P
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473919
[TBL] [Abstract][Full Text] [Related]
13. Comparison of single copy gene‑based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19‑directed CAR T cells in treated patients.
Schubert ML; Berger C; Kunz A; Schmitt A; Badbaran A; Neuber B; Zeschke S; Wang L; Riecken K; Hückelhoven-Krauss A; Müller I; Müller-Tidow C; Dreger P; Kröger N; Ayuk FA; Schmitt M; Fehse B
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35294040
[TBL] [Abstract][Full Text] [Related]
14. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma.
Oluwole OO; Jansen JP; Lin VW; Chan K; Keeping S; Navale L; Locke FL
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1581-1588. PubMed ID: 32561336
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas.
Riedell PA; Bishop MR
Ther Adv Hematol; 2020; 11():2040620720902899. PubMed ID: 32064069
[TBL] [Abstract][Full Text] [Related]
16. Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR.
Schubert ML; Kunz A; Schmitt A; Neuber B; Wang L; Hückelhoven-Krauss A; Langner S; Michels B; Wick A; Daniel V; Müller-Tidow C; Dreger P; Schmitt M
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33007926
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
[No Abstract] [Full Text] [Related]
18. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma.
Kato K; Makita S; Goto H; Kanda J; Fujii N; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
Int J Clin Oncol; 2022 Jan; 27(1):213-223. PubMed ID: 34599413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]